DNAVision: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
DNAVision
Largest movements
- Cash -€27,945
down €27,945 (-59.0%), from €47,396 to €19,451
mainly Net result for the year (-€73,752) and Receivables within one year (-€3,272)
- Receivables within one year +€3,272
up €3,272 (+66.6%), from €4,914 to €8,186
of which Trade receivables: +€7,258
- Profit (loss) carried forward -€73,752
down €73,752 (-8.5%), from -€867,589 to -€941,341
- Other debts +€50,000
up €50,000 (+5.9%), from €843,164 to €893,164
- Trade debts -€1,474
down €1,474 (-18.9%), from €7,786 to €6,312
- Gross operating margin -€48,726
down €48,726, from €44,995 to -€3,731
- Staff costs +€1,751
up €1,751 (+2.6%), from €66,235 to €67,986
- Depreciation -€1,429
no longer reported in 2025 (was €1,429)
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €52,772 | €27,822 | -€24,949 | -47.3% |
| Current assets | 29/58 | €52,772 | €27,822 | -€24,949 | -47.3% |
| Amounts receivable within one year | 40/41 | €4,914 | €8,186 | +€3,272 | +66.6% |
| Trade receivables | 40 | - | €7,258 | +€7,258 | |
| Other amounts receivable | 41 | €4,914 | €928 | -€3,986 | -81.1% |
| Cash at bank and in hand | 54/58 | €47,396 | €19,451 | -€27,945 | -59.0% |
| Deferred charges and accrued income | 490/1 | €462 | €185 | -€276 | -59.9% |
| Total equity and liabilities | 10/49 | €52,772 | €27,822 | -€24,949 | -47.3% |
| Equity | 10/15 | -€806,089 | -€879,841 | -€73,752 | -9.1% |
| Contributions | 10/11 | €61,500 | €61,500 | = | 0.0% |
| Capital | 10 | €61,500 | €61,500 | = | 0.0% |
| Issued capital | 100 | €61,500 | €61,500 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€867,589 | -€941,341 | -€73,752 | -8.5% |
| Amounts payable | 17/49 | €858,861 | €907,663 | +€48,802 | +5.7% |
| Amounts payable within one year | 42/48 | €858,861 | €907,663 | +€48,802 | +5.7% |
| Trade debts | 44 | €7,786 | €6,312 | -€1,474 | -18.9% |
| Suppliers | 440/4 | €7,786 | €6,312 | -€1,474 | -18.9% |
| Taxes, remuneration and social security | 45 | €7,911 | €8,188 | +€277 | +3.5% |
| Taxes | 450/3 | €157 | €174 | +€17 | +11.0% |
| Remuneration and social security | 454/9 | €7,754 | €8,013 | +€259 | +3.3% |
| Other amounts payable | 47/48 | €843,164 | €893,164 | +€50,000 | +5.9% |
| Remuneration, social security and pensions | 62 | €66,235 | €67,986 | +€1,751 | +2.6% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €1,429 | - | -€1,429 | |
| Other operating charges | 640/8 | €387 | €400 | +€12 | +3.2% |
| Gross operating margin | 9900 | €44,995 | -€3,731 | -€48,726 | |
| Operating profit (loss) | 9901 | -€23,057 | -€72,117 | -€49,060 | -212.8% |
| Financial income | 75/76B | €5 | - | -€5 | |
| Recurring financial income | 75 | €5 | - | -€5 | |
| Financial charges | 65/66B | €1,771 | €1,439 | -€332 | -18.7% |
| Recurring financial charges | 65 | €1,771 | €1,439 | -€332 | -18.7% |
| Profit (loss) for the period before taxes | 9903 | -€24,823 | -€73,556 | -€48,733 | -196.3% |
| Income taxes | 67/77 | €157 | €195 | +€38 | +24.3% |
| Profit (loss) for the period | 9904 | -€24,981 | -€73,752 | -€48,771 | -195.2% |
| Profit (loss) for the period to be appropriated | 9905 | -€24,981 | -€73,752 | -€48,771 | -195.2% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 7 October 2026 via checked.be.